XOMA Corporation (NasdaqGM:XOMA) acquired DSUVIA® of Talphera, Inc. (NasdaqGM:TLPH) for $8 million on January 18, 2024. As part of transaction, XOMA will receive 100% of all royalties and milestones related to DSUVIA® sales until the Company receives $20 million. Thereafter, XOMA fully retains the 15% royalty associated with DSUVIA® commercial sales, and the 75% royalties generated from DoD purchases will be shared equally between XOMA and Talphera, as will the remaining $116.5 million in potential milestone payments due from Alora Pharmaceuticals.

XOMA Corporation (NasdaqGM:XOMA) completed the acquisition of DSUVIA® of Talphera, Inc. (NasdaqGM:TLPH) on January 18, 2024.